These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
136 related items for PubMed ID: 8792040
1. 311C90 (Zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: a comparison of its absorption during a migraine attack and in a migraine-free period. Thomsen LL, Dixon R, Lassen LH, Gibbens M, Langemark M, Bendtsen L, Daugaard D, Olesen J. Cephalalgia; 1996 Jun; 16(4):270-5. PubMed ID: 8792040 [Abstract] [Full Text] [Related]
4. Can oral 311C90, a novel 5-HT1D agonist, prevent migraine headache when taken during an aura? Dowson A. Eur Neurol; 1996 Jun; 36 Suppl 2():28-31. PubMed ID: 8791030 [Abstract] [Full Text] [Related]
9. No need to adjust the dose of 311C90 (zolmitriptan), a novel anti-migraine treatment, in patients with renal failure not requiring dialysis. Gillotin C, Bagnis C, Mamet JP, Peck RW, Deray G. Int J Clin Pharmacol Ther; 1997 Nov; 35(11):522-6. PubMed ID: 9401835 [Abstract] [Full Text] [Related]
16. Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. International clinical experience based on > 3000 subjects treated with zolmitriptan. Edmeads JG, Millson DS. Cephalalgia; 1997 Oct; 17 Suppl 18():41-52. PubMed ID: 9399016 [Abstract] [Full Text] [Related]